This conference will explore new or improved therapeutic approaches for finding cures for diseases which traditionally have been difficult to treat. This includes technologies for optimizing treatments and monitoring efficacy based on insights into cell and tissue state, circuitry, behavior, function, and responsiveness in normal and disease states, biomarker detection, better methods to predict and track efficacy, and enhanced manufacturing capabilities.
Max Kanter, Cofounder & CEO, Feature Labs
Interpretable AI co-founders, Jack Dunn and Daisy Zhuo
MIT Startup Exchange presents its September Startup Workshop, centered around real-world IoT and edge computing. Many companies are grappling with how to use IoT and data/AI in their organization to monitor, predict, improve, and transform what they do. Meanwhile, many MIT startups are developing and providing innovative technology solutions to answer these very questions for industry. This workshop will present perspectives from industry leaders, academics, and corporate investors, while also showcasing select MIT startups in the field.
AI Driven Bloodless Blood Tests Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx GPx: https://gpx.ai/
In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has proven effective in reducing heart failure readmissions, but its use remains limited.
To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.
Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto University, Kobe University, and Kochi University.
Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology) and to assess the potential for providing algorithm-based services for heart failure patients within Japan.
Update - Looking for a few more startups to participate in the exhibit portion of the conference and interact with ILP Corporate Members in attendance.
[Looking for 8 Startups to Speak on Sept 22 at 2021 MIT Innovations in Management Conference (followed by Startup Lunch Exhibit)].
Procter & Gamble is looking for new approaches and technologies that can help them to address key business challenges/opportunities. The following innovation brief(s) will provide a high-level overview of specific business goals and needs, as well as a high-level overview of what they are looking for in a solution.